---

🔬 BPH & LUTS — Complete Clinical Deep-Dive

Your Senior Urologist Teaching Session — Campbell-Walsh Wein & Hinman's Atlas Level

---

PART 1: ANATOMY & PATHOPHYSIOLOGY — WHY BPH HAPPENS

Zonal Anatomy (McNeal's Zones — must internalize)

The Two-Component Obstruction Model

1. Static component — actual gland bulk (transition zone hyperplasia) → treated by 5-ARIs, ablative surgery
2. Dynamic component — smooth muscle tone in stroma and bladder neck (alpha-1 adrenoceptors) → treated by alpha-blockers

Hormonal Basis

• DHT (dihydrotestosterone) = the driver. Testosterone → DHT via 5-alpha reductase type 2 in prostatic stroma.
• Estrogen (from peripheral conversion of androgens) also plays a synergistic role in BPH development.
• This is why castrate men don't develop BPH — and why finasteride/dutasteride work (they block 5-AR).

---

PART 2: EPIDEMIOLOGY & RISK FACTORS

• Prevalence: ~50% of men by age 60, ~90% by age 85
• Risk factors: age, androgens, intact testes (universal triad)
• Additional: metabolic syndrome (PMID 39488266 — 2024 systematic review confirms independent association), obesity, type 2 DM, sedentary lifestyle
• Protective: physical activity, moderate alcohol intake (reduces DHT conversion modestly)

---

PART 3: SYMPTOMS — THE CLINICAL PICTURE

LUTS Classification (never mix these up in clinic)

Complications of Untreated/Progressive BPH

• Acute urinary retention (AUR) — precipitated by cold weather, anticholinergics, decongestants, opioids, constipation, anesthesia
• Chronic urinary retention — high PVR, painless (unlike AUR), can cause upper tract damage
• Bladder changes — trabeculation → cellules → diverticula → impaired contractility
• Recurrent UTI
• Bladder stones (urinary stasis → crystallisation)
• Renal insufficiency (bilateral hydroureteronephrosis from chronic high-pressure retention)
• Haematuria — from dilated surface veins on adenoma

---

PART 4: ASSESSMENT — THE SYSTEMATIC APPROACH

History — what to ask every BPH patient

1. IPSS questionnaire (7 symptom + 1 QoL question) — score 0–7 mild, 8–19 moderate, 20–35 severe
2. Symptom duration and progression
3. Previous urinary infections, haematuria, stones
4. Urological or pelvic surgery (urethral stricture risk)
5. Neurological history (Parkinson's, DM, spinal disease — neurogenic bladder mimics BPH)
6. Current medications: anticholinergics, antihistamines, alpha-agonists (decongestants), opioids — all worsen retention
7. Sexual function — baseline before starting any medication (5-ARIs cause ejaculatory dysfunction; alpha-blockers cause retrograde ejaculation)
8. Haematuria history — mandatory before attributing any haematuria to BPH alone

Examination

• DRE — size estimate (1 mL ≈ 1 gram; rough guide: walnut = ~20g, lemon = ~50g, orange = ~80g+); note consistency, symmetry, nodules (hard nodule = cancer until proven otherwise), loss of median sulcus
• Suprapubic palpation/percussion — palpable bladder = significant chronic retention
• Neurological exam — perianal sensation, anal tone (S2-S4), lower limb reflexes if neurogenic cause suspected
• External urethral meatus — phimosis/meatal stenosis can cause LUTS

Investigations — Mandatory vs Optional

• PSA > 1.5 ng/mL = prostate >30g (use 5-ARI)
• PSA > 1.6 ng/mL in BPH = predictor of disease progression and AUR risk
• PSA velocity >0.75 ng/mL/year = suspicious for cancer regardless of absolute value
• Free PSA < 15% = more suspicious for cancer (in the 4–10 ng/mL "grey zone")
• 5-ARIs halve PSA at 6 months — if PSA does NOT halve on dutasteride at 6 months, suspect cancer

---

PART 5: MEDICAL MANAGEMENT

Step 1 — When to treat medically vs. watchful waiting

• Watchful waiting (active surveillance): IPSS ≤7, no complications, minimal bother
  • Annual review, lifestyle modification: fluid restriction (esp. evening), reduce caffeine/alcohol, double voiding, bladder retraining

Step 2 — Pharmacological Arsenal

Alpha-1 Adrenoreceptor Blockers (Alpha-blockers)

5-Alpha Reductase Inhibitors (5-ARIs)

• Onset of benefit: 3–6 months (patients must be counselled — they will not notice benefit for months)
• Best for: prostate >40g or PSA >1.4–1.6 ng/mL
• Reduce AUR risk by 57% and need for surgery by 55% (MTOPS trial data)
• Side effects: decreased libido (6%), erectile dysfunction (8%), ejaculatory dysfunction, gynaecomastia (~1.5%), volume decrease in semen
• Cancer risk discussion: PCPT and REDUCE trials showed 5-ARIs reduce CaP incidence BUT slightly increase high-grade cancer detection (artifact of volume reduction/biopsy enhancement). Discuss this with patient.

Combination Therapy (Alpha-blocker + 5-ARI)

• CombAT and MTOPS trials: combination superior to monotherapy for reducing AUR risk, surgical progression, and symptom improvement over 4 years
• Indication: Prostate >40g + IPSS ≥8 + Qmax <15 mL/s — this is the patient you combine

PDE5 Inhibitors (Tadalafil 5 mg OD)

• FDA/EMA approved for BPH-LUTS ± erectile dysfunction
• Mechanism: Smooth muscle relaxation in prostate, bladder, urethra via NO-cGMP pathway
• IPSS improvement ~3–5 points; Qmax improvement modest
• Ideal patient: BPH-LUTS + erectile dysfunction — treat both with one pill
• Do NOT combine with alpha-blockers without careful BP monitoring (hypotension risk)

Antimuscarinics / Beta-3 Agonists (for storage symptoms)

• When storage symptoms dominate despite alpha-blocker therapy
• PVR >200–300 mL = caution/contraindication for antimuscarinics (risk of precipitating retention)
• Mirabegron (beta-3 agonist) preferred over antimuscarinics in BPH — lower retention risk
• Always check PVR before adding any anticholinergic to an older male

---

PART 6: SURGICAL MANAGEMENT — INDICATIONS & OVERVIEW

Absolute Indications for Surgery (don't observe these — operate)

1. Refractory AUR (failed at least one TWOC — trial without catheter)
2. Recurrent AUR (second episode)
3. Recurrent UTIs attributable to BPH
4. Bladder stones from stasis
5. Renal insufficiency due to obstruction (bilateral hydronephrosis/high-pressure retention)
6. Refractory haematuria from BPH
7. Large bladder diverticulum with incomplete emptying at risk of rupture

Relative Indications (patient choice + failed medical therapy)

• IPSS moderate-severe + failed/intolerant of medical therapy
• Patient preference for definitive treatment

---

PART 7: OPERATIVE TECHNIQUES — THE SURGEON'S WORKSHOP

🔧 TURP (Transurethral Resection of the Prostate)

Pre-op checklist (Senior tips)

• ✅ MSU must be sterile — treat any UTI first; sepsis post-TURP can be catastrophic
• ✅ Stop antiplatelets 7 days before (aspirin), warfarin 5 days; bridge with LMWH if needed
• ✅ Consent: bleeding, infection, TUR syndrome, retrograde ejaculation (permanent, ~75–90%), incontinence (<1%), stricture, recurrence, need for repeat procedure
• ✅ Ensure adequate equipment: monopolar vs. bipolar decision made pre-op
• ✅ Flexible cystoscopy done pre-op if any doubt about stricture

Positioning

• Lithotomy position — buttocks at the table edge (critical — if too far up, your scope can't reach anterior prostate)
• Pad legs carefully — common peroneal nerve compression is a real complication
• Use Lloyd-Davies/Allen stirrups; avoid excessive hip flexion

Monopolar TURP (M-TURP) — Step-by-step

• Survey the bladder: check for tumour, diverticula, bladder stones (deal with these now or stage separately)
• Identify: ureteral orifices, verumontanum, bladder neck, external sphincter

• Verumontanum = your most critical landmark — it marks the proximal end of the external sphincter. Never resect distal to it. This is where incontinence comes from.
• Bladder neck = your proximal limit — preserve bladder neck fibres to prevent excessive scarring/contracture

• Start at 11–1 o'clock (anterior), work laterally
• Resect bladder neck fibers last
• Systematic, clockwise deconstruction

• Create a channel at 5 or 7 o'clock down to the surgical capsule
• This sets your depth of resection — once you see the capsule, you know how deep to go
• Widen the channel laterally; lateral lobes will "fall" into the fossa as you resect
• Finish the floor (5–7 o'clock) last — avoid undermining the bladder neck

• Long, smooth strokes from bladder neck toward verumontanum
• Chips should be long and canoe-shaped — indicates full-depth, clean resection
• Short, jagged chips = too superficial or poor technique

• Use coagulation current for any visible bleeding vessels
• At end of resection, fill bladder fully and inspect at low pressure — venous bleeders only become visible at higher intravesical pressure

• Use Ellik evacuator to remove chips — multiple passes until clear
• Insert 3-way 22F or 24F catheter for CBI (continuous bladder irrigation)
• Balloon inflated to 30–50 mL in prostatic fossa and gentle traction helps tamponade venous bleeding

Bipolar TURP (B-TURP) — Key Differences

• Uses normal saline irrigant (iso-osmolar) → eliminates TUR syndrome
• Current contained at electrode → no grounding pad needed
• Active + return electrode in same loop (PlasmaKinetic system)
• Technique almost identical to M-TURP but faster haemostasis due to simultaneous cutting and vessel sealing
• Characteristic orange plasma glow around the loop — normal
• Slightly higher loop resistance on first contact ("drag") — especially with older generators

TUR Syndrome — Recognition and Management

• Under spinal: confusion, restlessness, nausea, visual disturbances (glycine toxicity to retina)
• Under GA: hypertension (early), then hypotension; bradycardia; rising CVP
• Serum Na+ <125 mEq/L = significant; <120 = emergency

1. Stop the resection immediately
2. Loop diuretic — IV furosemide 40–80 mg
3. Restrict fluids
4. Serum electrolytes stat
5. If Na <120 or symptomatic: hypertonic saline (3%) — correct at max 0.5–1 mEq/L/hour (rapid correction → central pontine myelinolysis)
6. ICU monitoring if severe

• Keep irrigant bags at minimum effective height (lower height = lower pressure = less absorption)
• Limit resection time — if you're at 60 min and not done, stop, pack the fossa, CBI overnight, and come back in 24–48 hours (staged TURP)
• For large prostates (>80g), plan for HoLEP or open prostatectomy, not TURP

---

🔧 HoLEP (Holmium Laser Enucleation of the Prostate)

• Wavelength: 2140 nm
• Chromophore: water (tissue absorption)
• Penetration depth: 0.4 mm (precise, no thermal spread)
• Mode: pulsed (contact technique)

• Works on any prostate size (80g, 150g, 200g — doesn't matter)
• Reduced blood loss (laser seals vessels as it cuts)
• Shorter catheterisation time
• Can be done on anticoagulation (warfarin, DOACs) without stopping
• Treats bladder stones with the same laser fibre

1. Identify your plane — at 5 and 7 o'clock, find the cleavage plane between adenoma and capsule
2. Enucleate the middle lobe first — incise at 5 and 7 o'clock from verumontanum to bladder neck; develop the plane with blunt and laser dissection; drop middle lobe into bladder
3. Right and left lateral lobe enucleation — systematic mobilisation of each lobe from capsule starting apically, preserving sphincter
4. Morcellation — once all tissue is in bladder, use morcellator (Versacut or similar) to chop tissue into small pieces for aspiration

• Apical dissection is the most critical step — stay right on the capsule, identify the sphincter, make sure you're not taking muscle fibres
• The verumontanum must be preserved — if you lose your veru orientation, stop and re-establish your landmarks from the bladder neck
• Bleeding during HoLEP is almost always venous — increase water bag height briefly to tamponade and then coagulate
• Mucosal button retention — if you see a button of mucosa at the apex between 11 and 1 o'clock, this is the apical mucosa. Some surgeons leave a small mucosal collar to protect the sphincter
• Catheter time: 18–24 hours (vs. 2–4 days for TURP) — patients love this

---

🔧 GreenLight PVP (KTP Laser Photovaporization)

• Wavelength: 532 nm (green)
• Chromophore: haemoglobin (highly absorbed)
• Penetration: 0.8 mm (slightly deeper than holmium)
• Vaporises tissue — NO chips, NO morcellator needed
• No histology available — this is important; if cancer suspected, get a biopsy first
• Excellent for anticoagulated patients — superb haemostasis
• Particularly good for prostate 30–80g

---

🔧 Open Simple Prostatectomy (Millin's Retropubic / Freyer's Suprapubic)

Millin's Retropubic Prostatectomy (most common open approach)

1. Approach: Pfannenstiel or lower midline incision; extraperitoneal, Retzius space development
2. Expose anterior prostatic capsule — ligate and divide dorsal venous complex (DVC)
3. Transverse anterior capsulotomy — 1–2 cm distal to bladder neck
4. Finger enucleation — develop the plane between adenoma and surgical capsule, sweeping with index finger circumferentially; watch out for the posterior commissure at the apex (sphincter)
5. Divide the urethra at the apex at the verumontanum level
6. Haemostasis — suture the bladder neck at 5 and 7 o'clock (bleeding points), running haemostatic suture in the prostatic fossa
7. Close capsule and insert urethral catheter (20–22F 3-way) and optional suprapubic catheter

• Use your index finger as a retractor inside the fossa — feel the capsule all around to ensure complete adenoma removal
• Posterior lip of bladder neck — avoid cutting too high; bladder neck contracture is common if the posterior lip sutures are too tight
• Leave the SPC for 5–7 days; remove urethral catheter at day 5, SPC when patient voiding well

---

PART 8: MINIMALLY INVASIVE & EMERGING TECHNOLOGIES

---

PART 9: POST-OPERATIVE MANAGEMENT & COMMON SCENARIOS

After TURP — Standard Care

• CBI (continuous bladder irrigation): run until effluent clears, typically 12–24 hours
• Catheter removal: Day 1–2 for bipolar; Day 2–3 for monopolar
• Haematuria after catheter removal is common at Days 7–14 (slough/eschar separation) — warn patient pre-op: "You'll notice some bleeding around 1–2 weeks — this is normal. Increase oral fluid intake. Only go to A&E if you cannot pass urine or pass clots that block your flow."
• Retrograde ejaculation — permanent in 75–90%; counsel before surgery; some patients wrongly assume this means infertility/incontinence (it doesn't mean incontinence)
• Return to work: desk job — 2 weeks; physical labour — 4–6 weeks
• No sexual activity for 4–6 weeks

Troubleshooting Scenarios

• Check PVR; if high, re-catheterise for 5–7 more days
• Causes: detrusor underactivity (long-standing obstruction), urethral clot, residual adenoma
• If fails repeat TWOC — check for bladder neck contracture or residual tissue at flexible cystoscopy

• Clot retention = bladder blocked with clots; patient straining, in pain
• Management: manual irrigation with bladder syringe (50mL Higginson syringe and 0.9% NaCl) — vigorous aspiration/irrigation to break up and evacuate clots
• If not clearing → return to theatre for cystoscopy, clot evacuation, and re-TURP any bleeding point
• Senior tip: Never try to force irrigant into a catheter if there's resistance — you may rupture the bladder. Check the catheter is in the bladder first with a gentle 5-10 mL bolus; feel for flow-back.

• Signs: increasing fluid deficit, loss of irrigant, patient discomfort (if awake), feeling of tissue giving way, visibility of fat/perivesical tissue in resection field
• Management:
  • Intraperitoneal perforation (rare, usually from anterior apical cut): stop, insert large catheter, decompress bladder, may need laparotomy/laparoscopy
  • Extraperitoneal perforation (more common): stop resection, insert catheter, CBI; usually resolves conservatively
• "30/30 rule": If fluid deficit >1L or resection time >60 min without completion, consider stopping

• Stop resecting. Evaluate the cause:
  1. Bleeding — coagulate the obvious vessel, then re-inspect
  2. Capsule opened — fat visible; stop
  3. Loop problem — check current settings, irrigant type
  4. Chip obstruction — evacuate via Ellik
• Never resect blindly — this is how you damage the sphincter or perforate

• Careful urethroscopy under vision
• Fine-calibre urethroscope (10F) to identify stricture
• Optical urethrotomy (Otis or direct vision internal urethrotomy) at same sitting
• If impassable — abort, SPC insertion, plan staged optical urethrotomy then TURP

---

PART 10: AUA/EAU GUIDELINES ALGORITHM — THE DECISION TREE

LUTS / BPH presentation
        ↓
Mandatory baseline: IPSS, DRE, PSA, Urinalysis, PVR, Uroflowmetry
        ↓
Any absolute surgical indications?
    YES → Surgical treatment
    NO ↓
IPSS 0–7 (mild)
    → Watchful waiting + lifestyle
IPSS 8–19 (moderate) or IPSS 20–35 (severe)
    ↓
Prostate <40g, PSA <1.5 → Alpha-blocker monotherapy
Prostate >40g, PSA >1.5 → Combination alpha-blocker + 5-ARI
Storage symptoms predominant + adequate Qmax → Consider adding mirabegron
ED + LUTS → Consider tadalafil
        ↓
Medical failure / patient preference for surgery
        ↓
Prostate 30–80g → TURP (bipolar preferred) or GreenLight PVP
Prostate >80g → HoLEP or Open Simple Prostatectomy
Patient refuses surgery / no middle lobe → UroLift or Rezūm
High surgical risk / very large prostate → PAE

---

PART 11: HIGH-YIELD EXAM TIPS & CLINICAL PEARLS

1. "TUR syndrome" = hyponatraemia — monopolar, glycine, long resection, high bag
2. Verumontanum = sphincter landmark — never resect distal to it
3. 5-ARIs halve PSA — if PSA doesn't halve at 6 months on dutasteride, investigate for cancer
4. TURP retrograde ejaculation = 75–90% — always counsel; it's expected
5. Alpha-blockers cause IFIS — warn ophthalmology before cataract surgery
6. HoLEP can treat any prostate size and is safe on anticoagulation
7. UroLift fails with middle lobe — screen pre-op
8. AUR treatment: catheterise → alpha-blocker → TWOC at 48h-2 weeks → if fails = surgery
9. Nocturia >2 voids → check 24h voiding diary — could be nocturnal polyuria, not BPH
10. Metabolic syndrome patients have faster BPH progression (2024 SR: PMID 39488266)
11. 20-year TURP meta-analysis (PMID 39547977, 2024): TURP remains the gold standard benchmark; improved safety with bipolar
12. Bladder outlet obstruction relief (PMID 38749852, Eur Urol 2024): combination therapy and surgical procedures show superior objective outcomes vs. monotherapy alone

---

Sources

• Campbell-Walsh-Wein Urology, 12th Edition — Chapters on BPH, TURP, Endoscopic Technology
• Hinman's Atlas of Urologic Surgery — HoLEP and Laser Procedures Chapter
• Smith & Tanagho's General Urology, 19th Edition — Interventional/IR Approaches
• PubMed: PMID 39547977 (TURP 20-year meta-analysis, 2024), PMID 38749852 (Eur Urol 2024), PMID 39488266 (Metabolic syndrome & BPH, 2024)

---

• Detailed urodynamics interpretation for BPH workup
• AUR management — full protocol with TWOC, alpha-blocker timing, emergency catheterisation tricks
• PSA interpretation in depth (prostate cancer vs BPH workup)
• Next topic — Urolithiasis, Prostate Cancer, Urological Emergencies, or any other chapter